Saturday 17 October 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
In the quarter to June 2026, EPS grew 58.7% and free cash flow fell 24.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.33
0.06
−1.37%
Follow CING
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(289.19%) | (450.60%) | (225.11%) | (198.74%) | |
| (186.14%) | (149.98%) | (128.82%) | (123.76%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(691.72%) | (656.13%) | (149.91%) | (124.06%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.28) | (3.48) | (2.02) | (1.59) | |
Free Cash Flow |
(17.79) | (17.61) | (19.77) | (20.94) | |
Capital Expenditures |
(0.06) | (0.36) | (0.22) | (0.28) | |
| Other line items | |||||
Cash ROIC |
(185.47%) | (120.47%) | (44.18%) | (40.37%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.77 | 0.70 | 0.72 | |
Depreciation/Fixed assets |
0.36 | 0.33 | 0.27 | 0.20 | |
Capex/Depreciation |
(0.11) | (0.64) | (0.49) | (0.88) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.26) | (3.41) | (2.00) | (1.57) | |
Capex per Share |
(0.01) | (0.07) | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates